In adults living with HIV, the 21-valent pneumococcal conjugate vaccine (PCV) V116 was well tolerated and effective against all 21 target serotypes. The immune responses were comparable to those ...
Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...
Pneumococcal conjugate vaccines (PCVs) reduce disease and colonization by the serotypes they cover. As of now, the Advisory Committee on Immunization Practices (ACIP) recommends that PCV15 and PCV20 ...
Pneumococcal community-acquired pneumonia (CAP) was a significant cause of hospitalizations in US adults, especially among those aged 65 years or older. This was largely due to Streptococcus ...
Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...
Sept 11 (Reuters) - Merck's (MRK.N), opens new tab pneumococcal vaccine triggered immune responses in children and teens who are at higher risk of serious illness in a late-stage study, the drugmaker ...
"We observed wide variation across pneumococcal conjugate vaccine (PCV) products in serotype coverage and potentially preventable burdens. Variation in both invasive and mucosal disease coverage and ...
Approved 15 months ago as a pneumococcal disease vaccine for adults—and billed as the first shot designed for seniors—Merck’s Capvaxive now has data supporting its potential in children and ...
Epidemiologist; Senior Research Fellow, National Centre for Immunisation Research and Surveillance; Conjoint Senior Lecturer, Faculty of Medicine, University of Sydney; NHMRC Emerging Leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback